Caspofungin
A semisynthetic echinocandin lipopeptide antifungal that inhibits fungal beta-1,3-D-glucan synthase, FDA approved on January 26, 2001 as Cancidas for refractory invasive aspergillosis and later for esophageal candidiasis, candidemia and empirical therapy in febrile neutropenia.
Also referenced as: Caspofungin acetate, MK-0991, Cancidas
Also appears in: Immune
Public product evidence No certificate records are bound to a tracked Caspofungin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Caspofungin product pages. Other certificates naming this compound may still exist — search the wider certificate database.This compound maps to at least one regulated medical product or label context in the United States.
Primary research area: Other. Also surfaces under Immune for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Caspofungin acetate, MK-0991, Cancidas
FDA label signal · 99 trials · 1000 PubMed results
Caspofungin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Caspofungin has 53 name-matched clinical trials (highest phase: Phase 4) and 1000 PubMed-indexed publications and holds an FDA drug label. 15 trials have posted results. Note: 1 retracted publication in the literature.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Caspofungin?
Caspofungin is a semisynthetic lipopeptide antifungal of the echinocandin class: a cyclic hexapeptide carrying a fatty acyl side chain that anchors the molecule in the fungal membrane next to its target enzyme. It is a semisynthetic derivative of pneumocandin B0, a lipophilic cyclic peptide isolated from fermentations of the fungus Glarea lozoyensis, which Merck’s chemists modified to improve its properties over a fifteen-year program covering 1985 to 2001 (Balkovec et al., Natural Product Reports, 2014;31(1):15–34). The marketed form is caspofungin acetate, with the empirical formula C52H88N10O15·2C2H4O2 and a formula weight of 1,213.42 according to the US label; the development code was MK-0991. It is supplied as a lyophilized powder for intravenous infusion only.
Caspofungin was the first echinocandin approved anywhere, and it established the class. Micafungin, anidulafungin and rezafungin are later echinocandins that share the same target and scaffold but are distinct molecules with their own approvals. Caspofungin is a hospital antifungal for serious Candida and Aspergillus infections; it has essentially no footprint in the research-peptide market.
How it works
- Inhibition of beta-1,3-D-glucan synthase. The US label describes caspofungin as an echinocandin that inhibits the synthesis of beta-1,3-D-glucan, an integral component of the fungal cell wall that mammalian cells do not make. The enzyme’s catalytic subunit is encoded by FKS1; Merck’s biochemists showed that disrupting one FKS1 allele in spontaneously pneumocandin-resistant Candida albicans mutants determined whether the resulting clones were resistant or sensitive, and that both alleles could not be inactivated, identifying Fks1p as an essential target of this inhibitor class (Douglas et al., Antimicrobial Agents and Chemotherapy, 1997;41(11):2471–2479).
- Stalling glucan translocation at the membrane interface. Cryo-EM structures of native Saccharomyces cerevisiae Fks1 show caspofungin forming a ternary complex with Fks1 and the nascent glucan chain at the membrane-protein interface, which suggests that the drug stalls polymer translocation rather than simply blocking the active site; the resistance substitution S643P destabilizes caspofungin and glucan binding through both allosteric perturbation and direct steric clash (Ren et al., Nature, 2026;654(8118):547–555).
- Fungicidal activity against Candida and resistance through FKS hot spots. Loss of beta-1,3-D-glucan weakens the wall of growing yeast cells, giving caspofungin fungicidal activity against Candida species (Mora-Duarte et al., New England Journal of Medicine, 2002;347(25):2020–2029). Resistance arises through amino acid changes in the “hot spot” regions of FKS-encoded glucan synthase subunits, remains rare in most Candida species but has reached higher levels in Candida glabrata, and is promoted by prophylaxis, gastrointestinal biofilm reservoirs and intra-abdominal infection (Perlin, Clinical Infectious Diseases, 2015;61 Suppl 6:S612–S617).
- Pharmacokinetics driven by distribution, not metabolism. In four phase 1 studies in healthy men, plasma concentrations rose proportionally with doses of 5 to 100 mg, the beta-phase half-life was 9 to 10 hours, clearance averaged 10 to 12 mL/min, and renal clearance of unchanged drug accounted for only about 2% of the dose (Stone et al., Antimicrobial Agents and Chemotherapy, 2002;46(3):739–745). The label adds a longer gamma phase with a half-life of 40 to 50 hours and notes that distribution rather than excretion or biotransformation dominates plasma clearance.
Research status
Esophageal candidiasis, the first clinical proof. The first demonstration of clinical utility for any echinocandin came from a multicenter, double-blind trial in adults with endoscopically documented Candida esophagitis: endoscopically verified clinical success was achieved in 74% and 89% of patients receiving caspofungin 50 and 70 mg/day, respectively, versus 63% on amphotericin B 0.5 mg/kg/day, and therapy was stopped for drug-related adverse events in 24% of the amphotericin B group against 4% and 7% of the caspofungin groups (Villanueva et al., Clinical Infectious Diseases, 2001;33(9):1529–1535). A second double-blind trial randomized 177 adults, 87% of them with HIV infection, to caspofungin 50 mg or fluconazole 200 mg intravenously once daily; favorable responses occurred in 81% versus 85% (difference −4%; 95% CI −15% to +8%), with symptomatic recurrence four weeks later in 28% versus 17% (Villanueva et al., American Journal of Medicine, 2002;113(4):294–299).
Salvage therapy for invasive aspergillosis. The original 2001 approval rested on an open-label study in 90 patients with invasive aspergillosis refractory to or intolerant of amphotericin B, its lipid formulations or triazoles. Among 83 evaluable patients, a favorable response was observed in 37 (45%), including 32 of 64 (50%) with pulmonary disease and 3 of 13 (23%) with disseminated disease; two patients discontinued for drug-related adverse events (Maertens et al., Clinical Infectious Diseases, 2004;39(11):1563–1571). The label still states that caspofungin has not been studied as initial therapy for invasive aspergillosis.
Invasive candidiasis and candidemia. The pivotal double-blind trial randomized 239 patients with invasive candidiasis to caspofungin or amphotericin B deoxycholate. In the 224-patient modified intention-to-treat analysis, successful outcomes occurred in 73.4% on caspofungin versus 61.7% on amphotericin B (adjusted difference 12.7 percentage points; 95.6% CI −0.7 to 26.0), with a favorable response in the candidemia subgroup of 71.7% versus 62.8%, and significantly fewer drug-related adverse events on caspofungin (Mora-Duarte et al., New England Journal of Medicine, 2002;347(25):2020–2029). A later double-blind comparison of a 150 mg/day regimen with the standard regimen in 204 patients found favorable responses in 77.9% versus 71.6% (difference 6.3%; 95% CI −5.9% to 18.4%, not significant) and no safety concerns at the higher dose (Betts et al., Clinical Infectious Diseases, 2009;48(12):1676–1684). In a head-to-head echinocandin trial, 595 adults with invasive candidiasis were randomized to micafungin 100 mg, micafungin 150 mg or standard-dose caspofungin; treatment success was 76.4%, 71.4% and 72.3%, with no significant differences in mortality, relapse or adverse events (Pappas et al., Clinical Infectious Diseases, 2007;45(7):883–893).
Empirical therapy in febrile neutropenia. A randomized, double-blind multinational trial compared caspofungin with liposomal amphotericin B in 1,095 evaluable patients with persistent fever and neutropenia. Overall success on a five-part composite endpoint was 33.9% versus 33.7% (95.2% CI for the difference −5.6 to 6.0%), meeting noninferiority criteria; among patients with baseline fungal infections, success was 51.9% versus 25.9% (P = 0.04), and nephrotoxicity (2.6% versus 11.5%) and infusion-related events (35.1% versus 51.6%) were both less frequent with caspofungin (Walsh et al., New England Journal of Medicine, 2004;351(14):1391–1402). This trial supported the September 29, 2004 approval of the empirical-therapy indication.
Pediatric development. A pharmacokinetic study in 39 neutropenic children and adolescents found that weight-based dosing at 1 mg/kg/day gave a 46% smaller 24-hour exposure than adults receiving 50 mg/day, while body-surface-area dosing at 50 mg/m2/day matched adult exposure consistently across ages (Walsh et al., Antimicrobial Agents and Chemotherapy, 2005;49(11):4536–4545). An open-label multicenter study then treated 49 patients aged 3 months to 17 years: success at the end of therapy was 5 of 10 with invasive aspergillosis, 30 of 37 with invasive candidiasis and 1 of 1 with esophageal candidiasis, with no serious drug-related adverse events or discontinuations for toxicity (Zaoutis et al., Pediatrics, 2009;123(3):877–884). A randomized, double-blind trial in 82 children aged 2 to 17 with persistent fever and neutropenia found caspofungin and liposomal amphotericin B comparable, with overall success of 46.4% versus 32.0% and serious drug-related adverse events in 1.8% versus 11.5% (Maertens et al., Pediatric Infectious Disease Journal, 2010;29(5):415–420). In 18 neonates and infants younger than 3 months, 25 mg/m2 once daily gave plasma exposures similar to adults on 50 mg/day, but the authors judged the sample too small for dosing recommendations (Sáez-Llorens et al., Antimicrobial Agents and Chemotherapy, 2009;53(3):869–875), and the US label still states that safety and effectiveness in this age group have not been established.
Regulatory path. The FDA approved Cancidas under NDA 021227 on January 26, 2001, initially for invasive aspergillosis in patients refractory to or intolerant of other therapies. Drugs@FDA records efficacy supplements for new indications approved on September 20, 2002 (esophageal candidiasis), January 7, 2003 (candidemia and other Candida infections) and September 29, 2004 (empirical therapy in febrile neutropenia), and efficacy supplement S-021, approved on July 29, 2008, that extended the indications to pediatric patients aged 3 months to 16 years. In the European Union, the product was authorized as Caspofungin MSD in October 2001 and later renamed Cancidas; in Japan, MSD K.K. received marketing approval for Cancidas 50 mg and 70 mg on January 18, 2012. Drugs@FDA now lists the Merck Cancidas vials as discontinued, with a Federal Register determination that the discontinuation was not for safety or effectiveness reasons, while caspofungin acetate for injection remains marketed under Fresenius Kabi’s NDA 206110 (approved December 30, 2016) and several abbreviated applications, the most recent approved on July 18, 2025. The most recent FDA actions on the molecule are generic approvals rather than new indications.
Common dosage forms
- Cancidas for injection. Single-dose vials of lyophilized caspofungin acetate powder containing 50 mg or 70 mg of caspofungin, for intravenous infusion in a hospital or infusion setting; the Merck brand is listed as discontinued in the US.
- Generic caspofungin acetate for injection. The same 50 mg and 70 mg single-dose lyophilized vials, marketed under Fresenius Kabi’s NDA and several abbreviated applications and administered intravenously by clinicians.
- No other presentation. No oral, inhaled, topical or compounded caspofungin product exists.
Key considerations
- Regulatory status. The FDA Approved status reflects the January 26, 2001 approval of Cancidas (caspofungin acetate) for injection under NDA 021227 for invasive aspergillosis refractory to or intolerant of other therapies. Later supplements added esophageal candidiasis, candidemia and other Candida infections, empirical therapy in febrile neutropenia and pediatric use from 3 months of age. The Merck brand vials are listed as discontinued for reasons other than safety or effectiveness, and generic caspofungin acetate for injection remains on the US market.
- A lipopeptide, not a classical peptide drug. Caspofungin is a fermentation-derived cyclic hexapeptide with a lipid tail, administered only intravenously and acting on a fungal cell-wall enzyme with no human counterpart; it is unrelated in origin and pharmacology to the hormone and signaling peptides that make up most of the research-peptide market.
- Hepatic signals and the cyclosporine interaction. The label reports liver enzyme abnormalities and transient transaminase elevations when caspofungin was given with cyclosporine. Exposure rose 1.76-fold after a single 70 mg dose in moderate hepatic insufficiency (Mistry et al., Journal of Clinical Pharmacology, 2007;47(8):951–961).
- Class-wide resistance. FKS hot-spot mutations in Candida glabrata and other Candida species reduce susceptibility to every echinocandin, not only caspofungin, and Cryptococcus species fall outside the echinocandin spectrum, so the drug’s useful spectrum is Candida and Aspergillus and prior echinocandin exposure, including prophylaxis, is the setting in which resistant isolates emerge.
- Class siblings are not aliases. Micafungin, anidulafungin and rezafungin share the echinocandin scaffold and target but are different molecules with separate approvals and labels; caspofungin, caspofungin acetate, MK-0991 and Cancidas all denote the same compound.